Source: ALL
Variant Gene Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs3814113
rs3814113 		A 0.820 GeneticVariation GWASDB Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. 23544013

2013
dbSNP: rs3814113
rs3814113 		A 0.820 GeneticVariation GWASCAT Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. 23544013

2013
dbSNP: rs3814113
rs3814113 		0.820 GeneticVariation GWASCAT GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. 23535730

2013
dbSNP: rs3814113
rs3814113 		0.820 GeneticVariation BEFREE To assess the potential implications of microRNAs in ovarian cancer, we investigated the associations between microRNA expression and seven ovarian cancer risk variants discovered from genome-wide association studies (GWAS), namely, rs3814113 on 9p22.2, rs2072590 on 2q31, rs2665390 on 3q25, rs10088218, rs1516982, rs10098821 on 8q24.21 and rs2363956 on 19p13. 22235027

2012
dbSNP: rs3814113
rs3814113 		0.820 GeneticVariation BEFREE A genome-wide association study recently identified an association between the rare allele of the single-nucleotide polymorphism (SNP) rs3814113 (ie, the C allele) at 9p22.2 and decreased risk of ovarian cancer for women in the general population. 21169536

2011
dbSNP: rs3814113
rs3814113 		T 0.820 GeneticVariation GWASCAT The most significant SNP (rs3814113; P = 2.5 x 10(-17)) was genotyped in a further 2,670 ovarian cancer cases and 4,668 controls, confirming its association (combined data odds ratio (OR) = 0.82, 95% confidence interval (CI) 0.79-0.86, P(trend) = 5.1 x 10(-19)). 19648919

2009
dbSNP: rs4691139
rs4691139 		G 0.800 GeneticVariation GWASCAT Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. 28346442

2017
dbSNP: rs17631303
rs17631303
PLEKHM1
G 0.800 GeneticVariation GWASDB In addition, we identified two novel ovarian cancer risk modifier loci: 17q21.31 (rs17631303, P = 1.4 × 10(-8), HR = 1.27, 95% CI: 1.17-1.38) and 4q32.3 (rs4691139, P = 3.4 × 10(-8), HR = 1.20, 95% CI: 1.17-1.38). 23544013

2013
dbSNP: rs17631303
rs17631303
PLEKHM1
G 0.800 GeneticVariation GWASCAT In addition, we identified two novel ovarian cancer risk modifier loci: 17q21.31 (rs17631303, P = 1.4 × 10(-8), HR = 1.27, 95% CI: 1.17-1.38) and 4q32.3 (rs4691139, P = 3.4 × 10(-8), HR = 1.20, 95% CI: 1.17-1.38). 23544013

2013
dbSNP: rs183211
rs183211
NSF ; LRRC37A2
A 0.800 GeneticVariation GWASDB Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. 23544013

2013
dbSNP: rs183211
rs183211
NSF ; LRRC37A2
A 0.800 GeneticVariation GWASCAT Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. 23544013

2013
dbSNP: rs4691139
rs4691139 		G 0.800 GeneticVariation GWASCAT In addition, we identified two novel ovarian cancer risk modifier loci: 17q21.31 (rs17631303, P = 1.4 × 10(-8), HR = 1.27, 95% CI: 1.17-1.38) and 4q32.3 (rs4691139, P = 3.4 × 10(-8), HR = 1.20, 95% CI: 1.17-1.38). 23544013

2013
dbSNP: rs4691139
rs4691139 		G 0.800 GeneticVariation GWASDB In addition, we identified two novel ovarian cancer risk modifier loci: 17q21.31 (rs17631303, P = 1.4 × 10(-8), HR = 1.27, 95% CI: 1.17-1.38) and 4q32.3 (rs4691139, P = 3.4 × 10(-8), HR = 1.20, 95% CI: 1.17-1.38). 23544013

2013
dbSNP: rs113488022
rs113488022
BRAF
0.750 GeneticVariation BEFREE Sustained response to vemurafenib in a low grade serous ovarian cancer with a BRAF V600E mutation. 26490654

2015
dbSNP: rs113488022
rs113488022
BRAF
0.750 GeneticVariation BEFREE In this study, we compared detection of the V600E mutation in serous ovarian tumors by VE1 immunostaining and by allele-specific polymerase chain reaction. 23089489

2013
dbSNP: rs113488022
rs113488022
BRAF
0.750 GeneticVariation BEFREE The presence of the BRAF V600E mutation in SB/LGS ovarian cancer was associated with early stage disease and improved prognosis. 22930283

2013
dbSNP: rs113488022
rs113488022
BRAF
0.750 GeneticVariation BEFREE No BRAF V600E mutations were detected in nonserous epithelial ovarian tumors. 22820660

2013
dbSNP: rs113488022
rs113488022
BRAF
T 0.750 CausalMutation CLINVAR Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. 22608338

2012
dbSNP: rs113488022
rs113488022
BRAF
T 0.750 CausalMutation CLINVAR Improved survival with vemurafenib in melanoma with BRAF V600E mutation. 21639808

2011
dbSNP: rs113488022
rs113488022
BRAF
T 0.750 CausalMutation CLINVAR Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm. 21683865

2011
dbSNP: rs113488022
rs113488022
BRAF
T 0.750 CausalMutation CLINVAR Epidermal growth factor receptor blockers for the treatment of ovarian cancer. 21975775

2011
dbSNP: rs113488022
rs113488022
BRAF
0.750 GeneticVariation BEFREE One recurrent somatic mutation, p.V600E, is frequently found in several tumor types, such as melanoma, papillary thyroid carcinoma, colon cancer, and ovarian cancer. 20735442

2011
dbSNP: rs113488022
rs113488022
BRAF
T 0.750 CausalMutation CLINVAR Inhibition of mutated, activated BRAF in metastatic melanoma. 20818844

2010
dbSNP: rs113488022
rs113488022
BRAF
T 0.750 CausalMutation CLINVAR KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer. 19018267

2008
dbSNP: rs113488022
rs113488022
BRAF
T 0.750 CausalMutation CLINVAR Mutations of the BRAF gene in human cancer. 12068308

2002